165 related articles for article (PubMed ID: 27166606)
1. Novel approaches to delivering value in oncology drugs.
Miller S
Clin Adv Hematol Oncol; 2016 Apr; 14(4):244-6. PubMed ID: 27166606
[No Abstract] [Full Text] [Related]
2. Reforming the payment system for medical oncology.
Bach PB
JAMA; 2013 Jul; 310(3):261-2. PubMed ID: 23817729
[No Abstract] [Full Text] [Related]
3. Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology.
American Society of Clinical Oncology
J Oncol Pract; 2014 Jul; 10(4):259-63. PubMed ID: 24737877
[No Abstract] [Full Text] [Related]
4. Three Steps Toward a More Sustainable Path for Targeted Cancer Drugs.
Bekelman JE; Joffe S
JAMA; 2018 Jun; 319(21):2167-2168. PubMed ID: 29710240
[No Abstract] [Full Text] [Related]
5. Medicare cost containment strategy targets several oncology drugs.
Twombly R
J Natl Cancer Inst; 2004 Sep; 96(17):1268-70. PubMed ID: 15339960
[No Abstract] [Full Text] [Related]
6. The shortage of essential chemotherapy drugs in the United States.
Gatesman ML; Smith TJ
N Engl J Med; 2011 Nov; 365(18):1653-5. PubMed ID: 22040130
[No Abstract] [Full Text] [Related]
7. Recent legislation changes the economics of cancer care.
Silberman G; Downs CG
ONS News; 2005 Jul; 20(7):9. PubMed ID: 16045235
[No Abstract] [Full Text] [Related]
8. Medicare and drug pricing.
Iglehart JK
N Engl J Med; 2003 Apr; 348(16):1590-7. PubMed ID: 12700381
[No Abstract] [Full Text] [Related]
9. Keynote comment: Cancer drug pricing in the USA.
Johnson DH
Lancet Oncol; 2006 Jun; 7(6):444-5. PubMed ID: 16750490
[No Abstract] [Full Text] [Related]
10. Biosimilars in Oncology: Reality Could Bite the Copycats, Dog Potential Major Savings.
Kelley T
Manag Care; 2017 Mar; 26(3):28-30. PubMed ID: 28510517
[TBL] [Abstract][Full Text] [Related]
11. Tackling Cost: A Prescription for Spending Wisely.
Tempero M
J Natl Compr Canc Netw; 2019 Jun; 17(6):633. PubMed ID: 31200360
[No Abstract] [Full Text] [Related]
12. Can cancer care lead the way toward a value-based future?
Macmillan K
Am J Manag Care; 2019 Dec; 25(12 Spec No.):SP377-SP378. PubMed ID: 31860249
[No Abstract] [Full Text] [Related]
13. Reimbursement: current status and future outlook.
Bailes JS
Semin Oncol; 1994 Aug; 21(4 Suppl 7):118-22. PubMed ID: 8091237
[TBL] [Abstract][Full Text] [Related]
14. Navigating the business of oncology for 2008.
Crisafulli T
Semin Oncol; 2008 Feb; 35(1):1-5. PubMed ID: 18308138
[No Abstract] [Full Text] [Related]
15. When will the U.S. flinch at cancer drug prices?
Vanchieri C
J Natl Cancer Inst; 2005 May; 97(9):624-6. PubMed ID: 15870428
[No Abstract] [Full Text] [Related]
16. Value and payment for oncology in the United States.
Robinson JC
Ann Pharm Fr; 2013 Sep; 71(5):285-90. PubMed ID: 24075699
[TBL] [Abstract][Full Text] [Related]
17. Healthcare reimbursement for oncology care.
Bence S
Pa Nurse; 2006 Jun; 61(2):17, 29. PubMed ID: 16871983
[No Abstract] [Full Text] [Related]
18. Robbing Peter to pay Paul? Financial reimbursement for chemotherapy.
Arceci RJ
J Pediatr Hematol Oncol; 2003 Apr; 25(4):277-8. PubMed ID: 12679638
[No Abstract] [Full Text] [Related]
19. The high cost of cancer drugs and what we can do about it.
Siddiqui M; Rajkumar SV
Mayo Clin Proc; 2012 Oct; 87(10):935-43. PubMed ID: 23036669
[No Abstract] [Full Text] [Related]
20. Oncology drug pricing structure is broken.
Hutchinson L
Nat Rev Clin Oncol; 2015 Sep; 12(9):499. PubMed ID: 26309071
[No Abstract] [Full Text] [Related]
[Next] [New Search]
